Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pepinemab (VX15)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Vaccinex

Drug class:

SEMA4D inhibitor

‹

›

PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3
PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + VX15 Sensitive: C3 – Early Trials pembrolizumab + VX15 Sensitive : C3	pembrolizumab + VX15 Sensitive: C3 – Early Trials pembrolizumab + VX15 Sensitive : C3